Sign in

You're signed outSign in or to get full access.

NI

NanoVibronix, Inc. (NAOV)·Q3 2020 Earnings Summary

Executive Summary

  • Q3 2020 revenue grew 49% year over year to $0.15M, while gross margin rebounded to 66% from 14% in Q2 as steep discounts ended; net loss was $0.92M ($0.10 per share). Sequentially, revenue declined from Q2’s $0.27M given Q2’s one-time discounted sale that depressed margins .
  • Commercial execution improved: new PainShield Plus, expanded U.S. DME distribution, VA Federal Supply Schedule listing, CMS Medicare reimbursement codes, first U.K. UroShield shipments, and FDA enforcement discretion enabling UroShield U.S. distribution during COVID-19 .
  • Liquidity strengthened: $3.2M cash at quarter-end following ~$4.1M net equity issuance; subsequent December private placement authorized up to $6.0M of shares and pre-funded warrants to further bolster capital .
  • Nasdaq listing risk mitigated near term via extension through Dec 15, 2020 to regain equity compliance—an important technical overhang for the stock .
  • Catalyst path: expanded private-label DME agreement increased minimum purchase targets from $1.1M (2 years) to $7.8M (3 years), with initial sales expected to begin in Q2 2021; regulatory and reimbursement progress supports adoption of opioid-sparing therapies amid COVID-19 .

What Went Well and What Went Wrong

What Went Well

  • Gross margin expanded to 66% (from 47% YoY and 14% in Q2) on more advantageous distributor pricing versus prior-period discounts; Q3 gross profit was $99K on $150K revenue .
  • Distribution and reimbursement momentum: VA Federal Supply Schedule listing; CMS Medicare reimbursement codes for PainShield; expanded U.S. DME channel (UPPI) with private-label PainShield and PainShield Plus .
  • CEO highlighted progress: “broader commercialization... new and expanded distribution agreements, lower cost manufacturing, clearance of regulatory hurdles and marketing and branding programs... create a strong catalyst for additional growth” .

What Went Wrong

  • Sequential revenue decline: Q3 revenue $0.15M vs Q2 $0.27M, reflecting normalization after Q2’s discounted sale; net loss remained elevated at $0.92M .
  • Operating expenses increased YoY (S&M +27%) as marketing restarted post-August capital raise, keeping operating loss at $(0.80)M despite margin recovery .
  • Ongoing listing and governance risks: Nasdaq equity deficiency extension; material weaknesses in disclosure controls remained unremediated in Q3; bid-price deficiency letter received in November .

Financial Results

MetricQ3 2019Q2 2020Q3 2020
Revenue ($USD Thousands)$101 $269 $150
Gross Profit ($USD Thousands)$47 $38 $99
Gross Margin (%)47% 14% 66%
Total Operating Expenses ($USD Thousands)$840 $1,506 $903
Loss from Operations ($USD Thousands)$(793) $(1,468) $(804)
Net Loss ($USD Thousands)$(815) $(1,477) $(922)
EPS (Basic & Diluted, $USD)$(0.12) $(0.20) $(0.10)

Segment/geography breakdown (revenue):

GeographyQ3 2019 ($USD Thousands)Q3 2020 ($USD Thousands)
United States$101 $130
Europe$0 $17
Israel$0 $1
India$0 $2
Canada$0 $0
From distributors (% of total)93% 85%

KPIs:

KPIQ3 2019Q3 2020
Disposable products (% of revenue)12% 7%
PainShield share of revenueNot disclosed100%
Interest expense ($USD Thousands)$0 $123 (warrant amortization on note repaid in Q3)
Cash & Equivalents ($USD Millions)—$3.2

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
UPPI private-label DME purchase targets2021–2023$1.1M over 2 years (original agreement) $7.8M over 3 years (amended & restated) Raised
UroShield U.S. distribution authorizationCOVID-19 periodNot authorized for U.S. saleFDA enforcement discretion allows U.S. distribution (limited use) New authorization
Nasdaq continued listingThrough Dec 15, 2020Non-compliant with $2.5M equity requirementExtension granted to evidence compliance Extension

Note: No formal quantitative revenue/EPS/margin guidance ranges were provided in Q3 materials .

Earnings Call Themes & Trends

No Q3 2020 earnings call transcript was found in our document set; themes are drawn from Q2 and Q3 10-Qs and press releases.

TopicPrevious Mentions (Q2 2020)Current Period (Q3 2020)Trend
Supply chain/COVID60-day shutdown at China manufacturer; CE mark delays; resumed in April; margin hit from steep Q2 discounts Production delays no longer present; monitoring resurgence risk; remote administration benefits emphasized Improving operations; macro risk persists
RegulatoryCE mark approved in April 2020 FDA enforcement discretion enabling UroShield U.S. distribution during COVID-19 Positive regulatory momentum
Reimbursement/ChannelsDME distribution agreement (UPPI) signed in June; workers' comp and insurance channels noted VA FSS listing; CMS Medicare code; UPPI agreement expanded with private label and higher minimums Strengthening access and minimums
Product performancePainShield 100% of revenue; margin depressed by discounts PainShield Plus introduced; margin recovery on improved pricing Expanded portfolio; margin recovery
Legal/NasdaqOngoing litigation in Israel; Nasdaq equity deficiency hearing scheduled Nasdaq extension granted; bid-price deficiency letter (Nov) Technical listing overhang persists

Management Commentary

  • “We are making great strides towards broader commercialization... new and expanded distribution agreements, lower cost manufacturing, clearance of regulatory hurdles and marketing and branding programs... could elevate our business to the next level in the near term” — Brian Murphy, CEO .
  • “Our products have been added to the U.S. Veterans’ Administration Federal Supply Schedule (FSS) and are now reimbursable under CMS Medicare reimbursement codes creating a pathway for expanded distribution through government channels” — Brian Murphy, CEO .
  • “The resurgence in Covid-19 cases further reinforces the need for alternative pain therapies that can be administered safely and remotely... we continue to execute on our strategy and pursue promising opportunities” — Brian Murphy, CEO .

Q&A Highlights

No Q3 2020 earnings call transcript was found; therefore, Q&A highlights and any call-based guidance clarifications are unavailable in the current document set.

Estimates Context

Wall Street consensus (S&P Global) for Q3 2020 EPS and revenue was not available via our SPGI access for NAOV at this time (data request limit hit). As a micro-cap, NAOV may have limited analyst coverage; we anchor analysis to reported results and management commentary [GetEstimates error].

Key Takeaways for Investors

  • Margin inflection: gross margin rebounded to 66% in Q3 from 14% in Q2 as steep discounts ended; this improved unit economics despite modest revenue ($0.15M) .
  • Sequential normalization: revenue fell from Q2’s $0.27M to $0.15M as the discounted distributor shipment rolled off; YoY growth was strong (+49%) .
  • Channel/reimbursement momentum: VA FSS listing and CMS Medicare codes should support PainShield adoption in government channels; UPPI DME network expands reach .
  • Private-label UPPI agreement materially raises minimum purchase targets to $7.8M over three years, with initial sales expected to begin in Q2 2021—key revenue visibility lever .
  • Regulatory tailwind: FDA enforcement discretion enables UroShield U.S. availability during COVID, adding potential incremental demand in catheter care .
  • Balance sheet improved: $3.2M cash at Q3-end after ~$4.1M net equity raises; December private placement authorized up to $6.0M more—supports scaling and marketing .
  • Listing risk present but managed: Nasdaq equity extension and later bid-price notice highlight technical risks; continued execution and capital actions remain important for compliance .